Propanc Biopharma has secured $100 million in financing from Hexstone Capital to enhance its digital asset strategy. The investment will support the company’s efforts to expand its digital asset portfolio and accelerate research in cancer treatment. Propanc aims to acquire undervalued Digital Asset Treasury companies to drive shareholder value.

Leave a Reply